Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: aprepitant

« Back to Dashboard
Aprepitant is the generic ingredient in two branded drugs marketed by Sandoz and Merck, and is included in two NDAs. There are three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and seventy-three patent family members in fifty-two countries.

There are eighteen drug master file entries for aprepitant. Three suppliers are listed for this compound.

Summary for Generic Name: aprepitant

Tradenames:2
Patents:3
Applicants:2
NDAs:2
Drug Master File Entries: see list18
Suppliers / Packaging: see list13
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details

Clinical Trials for: aprepitant

Efficacy of Aprepitant (Emend®) in Children
Status: Recruiting Condition: Nausea; Vomiting; Childhood Cancer

Topical Aprepitant in Prurigo Patients
Status: Completed Condition: Pruritus

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Status: Terminated Condition: Chemotherapy-Induced Nausea and Vomiting

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Status: Completed Condition: Lymphoma

Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
Status: Completed Condition: Chemotherapy Induced Nausea and Vomiting

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects
Status: Recruiting Condition: HIV Infection

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
Status: Completed Condition: Postoperative Nausea and Vomiting

Aprepitant Effects on Oxycodone Response
Status: Completed Condition: Narcotic Abuse

A Study to Evaluate Aprepitant for the Prevention of Post Operative Nausea and Vomiting in Children (MK-0869-219)
Status: Recruiting Condition: Post-Operative Nausea; Post-Operative Vomiting

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting (CINV)

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-002Mar 26, 2003RXYes5,719,147<disabled>YY<disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-003Jun 30, 2006RXNo8,258,132<disabled>Y<disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-001Mar 26, 2003RXNo8,258,132<disabled>Y<disabled>
Sandoz
APREPITANT
aprepitant
CAPSULE;ORAL090999-001Sep 24, 2012RXNo<disabled><disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-001Mar 26, 2003RXNo6,096,742<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: aprepitant

Country Document Number Publication Date
Israel106142Mar 18, 1997
China1106390Apr 23, 2003
JapanH09506628Jun 30, 1997
Poland182521Jan 31, 2002
Brazil9810360Jan 30, 2001
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc